Home/Filings/4/0001178913-18-000259
4//SEC Filing

Hazot Yohan 4

Accession 0001178913-18-000259

CIK 0001606645other

Filed

Jan 23, 7:00 PM ET

Accepted

Jan 24, 8:21 PM ET

Size

12.2 KB

Accession

0001178913-18-000259

Insider Transaction Report

Form 4
Period: 2018-01-01
Hazot Yohan
VP Pharmaceutical Development
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2018-01-15+56227,300 total
  • Exercise/Conversion

    Ordinary Shares

    2018-01-01+4,57527,300 total
  • Exercise/Conversion

    Restricted Share Units

    2018-01-014,5750 total
    Exercise: $0.00Ordinary Shares (4,575 underlying)
  • Exercise/Conversion

    Restricted Share Units

    2018-01-155620 total
    Exercise: $0.00Ordinary Shares (562 underlying)
Footnotes (5)
  • [F1]This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
  • [F2]The issuer's method of reporting restricted share units has been revised to report such grants in Table I rather than as previously reported in Table II. Accordingly, this amount includes (i) 6,184 ordinary shares previously reported in Table I of the reporting person's Form 3, (ii) 4,575 ordinary shares underlying restricted share units that vested on January 1, 2018, (iii) 562 ordinary shares underlying restricted share units that vested on January 15, 2018 and (iv) 15,979 ordinary shares subject to unvested restricted share units that were previously reported in Table II of the reporting person's Form 3 as a derivative security.
  • [F3]The ordinary shares underlying this restricted share unit award vest over a period of four years (25% on January 1, 2018 and 6.25% every three months thereafter) ending January 1, 2021.
  • [F4]The ordinary shares underlying this restricted share unit award vest in equal installments every three months over the vesting period beginning January 15, 2018 and ending January 15, 2019.
  • [F5]This class of restricted share units is included in Column 5 of Table I above.

Issuer

Foamix Pharmaceuticals Ltd.

CIK 0001606645

Entity typeother

Related Parties

1
  • filerCIK 0001727759

Filing Metadata

Form type
4
Filed
Jan 23, 7:00 PM ET
Accepted
Jan 24, 8:21 PM ET
Size
12.2 KB